Analysis of the Psychometric Properties of Kinematic Parameters of Locomotion Measured by Inertial Measurement Units. Validation in Healthy Children and Children with Cerebral Palsy

NCT ID: NCT06138925

Last Updated: 2025-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-31

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cerebral palsy (CP) is currently one of the major causes of disability in children. The presence of various disorders (muscle stiffness, architectural bone defects, spasticity) leads to a number of functional impacts, including severe impairment of mobility, particularly locomotion. Locomotion can be assessed using a motion capture system that enables 3-dimensional analysis, in order to help make treatment decisions and quantify them. Although these systems are currently considered to be the gold standard, the fact remains that they cause a certain amount of patient fatigue (long set-up times) and that walking is assessed in a laboratory rather than in real life.

Today, technological advances have brought to the fore other gait analysis devices, such as inertial measurement units (IMUs). Various systems incorporating IMUs in the feet, for example, respond to these problems of analysing walking in real-life situations. The IMUs record the movements and orientation of the foot in space; the data is then processed by algorithms to recognise walking steps and calculate the spatio-temporal parameters of locomotion. Additional IMUs positioned on the body can be grafted onto this system to provide a more precise analysis of locomotion, in particular by calculating the movements of the various joints of the lower limb. However, before such devices can be used in a pathological paediatric population, they must be validated in a healthy population. This validation must be conducted using a precise method that has been widely documented in the COSMIN recommendations (Consensus-based Standards for the selection of health Measurement Instruments). The first stage will assess the safety of the IMU devices in a healthy paediatric population, and the validity of the spatio-temporal parameters. If these properties are deemed to be compliant, these same parameters will be assessed in a paediatric population with cerebral palsy in the second stage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Palsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy children

Group Type ACTIVE_COMPARATOR

Analysis of walking

Intervention Type OTHER

3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)

Analysis of running

Intervention Type OTHER

analysis of running on flat ground at different speeds (comfortable and fast)

hildren with cerebral palsy

Group Type EXPERIMENTAL

Analysis of walking

Intervention Type OTHER

3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Analysis of walking

3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)

Intervention Type OTHER

Analysis of running

analysis of running on flat ground at different speeds (comfortable and fast)

Intervention Type OTHER

Analysis of walking

3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children who have given their consent and whose legal representatives have given their consent
* Age between 7 and 17 years,
* Children able to understand simple commands and instructions.
* Children living within a maximum radius of 50 km of the investigation site.
* Child covered by national health insurance.

PATIENT GROUP (IN ADDITION TO THOSE ABOVE)

* Children with proven cerebral palsy resulting in locomotor impairment but able to move around without technical aids (cane, wheelchair).
* Child covered by national health insurance.

Exclusion Criteria

* Children with a condition other than cerebral palsy that affects their ability to walk.
* Child subject to a measure of legal protection
* A child unable to give consent
* Pregnant, parturient or breast-feeding participant
Minimum Eligible Age

7 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Dijon Bourgogne

Dijon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Paul ORNETTI

Role: CONTACT

03 80 29 38 72 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mathieu GUEUGNON

Role: primary

03 80 29 38 72 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ORNETTI 2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.